PERSONALISED MEDICINE CONSORTIUM

The Personalised Medicine Consortium (PMC) of Luxembourg is an initiative with the aim to support research and to make Luxembourg a leader in the adoption of personalised medicine into the national healthcare system. It brings together the Luxembourg Institute of Health (LIH), the LCSB (Luxembourg Centre for Systems Biomedicine) and IBBL (Integrated BioBank of Luxembourg) and is led by an Executive Board consisting of Dr Catherine Larue (CEO of LIH), Prof Rudi Balling (CEO of LCSB) and Marc Vandelaer (CEO of IBBL). The PMC’s initial areas of focus were cancer, diabetes and Parkinson’s disease and multiple collaborative projects were successfully launched and executed. Recently the scope of the PMC has been extended to include other diseases and areas of interest (e.g. big data).

The PMC Fund

The PMC is keen to build new collaborations between clinicians and researchers from Luxembourg and to foster new synergies. To aid in this process, the PMC has developed a fund to ‘pump prime’ new initiatives. This program was successfully trialled in 2014/2015 and and the winner of the 2016 PMC Pump Prime Fund was recently announced at the PMC’s Annual Meeting (see article below).

The expectation is that the funding will be used to initiate new collaborative research projects on biomedical research between clinicians and researchers and who are based in different research institutions. Priority will be given to projects that are novel and innovative, that are establishing new collaborations within Luxembourg and where preliminary data is needed prior to submitting an application to an external funding agency.

The main expected return on investment of such funding relies on:

  • Ÿ Solving unmet clinical needs with innovative approach
  • Ÿ Fostering research interactions between the three biomedical research institutes of Luxembourg.
  • Ÿ Enabling researchers/clinicians to develop this project into an externally funding project if successful

Practical Information

A minimum of two of the PMC funding organisations (IBBL-LIH-LCSB) must be involved in each funding application (ideally three). For full details about the call, the conditions of eligibility and the application process, you can download the PMC FUND Overview & Guidelines.

Call deadlines

The call for the 2016 PMC Pump Prime closed in October 2015 and the winner has been announced at the PMC’s Annual Meeting.

Call documents

Contact

If you have any question, please contact Angela HOGAN:

Tel:  +352 27 44 64 42
Email: pmc@ibbl.lu

You may be interested in:

  • Personalised Medicine Consortium Meeting 2015

    The Personalised Medicine Consortium (PMC), composed of the national biomedical research institutions, aims to build new collaborations […]

    READ MORE
  • Progress for early detection of colon cancer

    Three years of successful collaboration between Luxembourg’s researchers, clinicians and IBBL (Integrated BioBank of Luxembourg) have led […]

    READ MORE
  • Shaping Europe’s Vision for Personalised Medicine

    Considered a European expert on biomarkers, IBBL’s CEO, Dr Catherine Larue, was asked to contribute to the […]

    READ MORE